Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines

Vaccine

Volumn 28, Issue 8, 2010, Pages 2011-2019

  Wang, Shixia ^a   Mboudjeka, Innocent ^a   Goguen, Jon D ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antigen engineering; DNA vaccine; Plague; Yersina pestis

Indexed keywords

ANTIBODY; ANTIGEN; DNA VACCINE; SIGNAL PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DESIGN; DRUG POTENTIATION; FEMALE; GENE INSERTION; GENE SEQUENCE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNITY; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; YERSINIA PESTIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CELL LINE; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VIRULENCE FACTORS; YERSINIA PESTIS;

EID: 76949088967     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.059     Document Type: Article

References (42)

1. Meyer K.F., Cavanaugh D.C., Bartelloni P.J., and Marshall Jr. J.D. Plague immunization. I. Past and present trends. J Infect Dis 129 May (Suppl.) (1974) S13-S18
2. Reisman R.E. Allergic reactions due to plague vaccine. J Allergy 46 July (1) (1970) 49-55
3. Marshall Jr. J.D., Bartelloni P.J., Cavanaugh D.C., Kadull P.J., and Meyer K.F. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J Infect Dis 129 May (Suppl.) (1974) S19-S25
4. Williams J.E., Altieri P.L., Berman S., Lowenthal J.P., and Cavanaugh D.C. Potency of killed plague vaccines prepared from avirulent Yersinia pestis. Bull World Health Organ 58 5 (1980) 753-756
5. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 July (11-12) (1998) 1131-1137
6. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 December (3-4) (1995) 223-230
7. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 July (10) (1997) 1079-1084
8. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19 October (4-5) (2000) 566-571
9. Glynn A., Roy C.J., Powell B.S., Adamovicz J.J., Freytag L.C., and Clements J.D. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73 August (8) (2005 Aug) 5256-5261
10. Glynn A., Freytag L.C., and Clements J.D. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 March (16) (2005) 1957-1965
11. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., and Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63 August (8) (1995) 2854-2858
12. Jones S.M., Griffin K.F., Hodgson I., and Williamson E.D. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21 September (25-26) (2003) 3912-3918
13. Eyles J.E., Williamson E.D., Spiers I.D., and Alpar H.O. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 18 August (28) (2000) 3266-3271
14. Williamson E.D., Flick-Smith H.C., Lebutt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 June (6) (2005) 3598-3608
15. Matson J.S., Durick K.A., Bradley D.S., and Nilles M.L. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol 5 (2005) 38
16. Swietnicki W., Powell B.S., and Goodin J. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague. Protein Expr Purif 42 July (1) (2005) 166-172
17. Wang S., Joshi S., Mboudjeka I., Liu F., Ling T., Goguen J.D., et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine 26 March (13) (2008) 1664-1674
18. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26 July (31) (2008) 3947-3957
19. Lu S., Wang S., and Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7 March (2) (2008) 175-191
20. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 4 November-December (6) (2008) 449-452
21. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205 January (1) (2008) 63-77
22. Garmory H.S., Freeman D., Brown K.A., and Titball R.W. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen. Vaccine 22 February (8) (2004) 947-957
23. Grosfeld H., Bino T., Flashner Y., Ber R., Mamroud E., Lustig S., et al. Vaccination with plasmid DNA expressing the Yersinia pestis capsular protein F1 protects mice against plague. Adv Exp Med Biol 529 (2003) 423-424
24. Grosfeld H., Cohen S., Bino T., Flashner Y., Ber R., Mamroud E., et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun 71 January (1) (2003) 374-383
25. Wang S., Heilman D., Liu F., Giehl T., Joshi S., Huang X., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 September (25-26) (2004) 3348-3357
26. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24 May (21) (2006) 4531-4540
27. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 February (2) (1998) 1497-1503
28. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 6 March (3) (1996) 315-324
29. Kutzler M.A., and Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev 9 October (10) (2008) 776-788
30. Wang S., Taaffe J., Parker C., Solorzano A., Cao H., Garcia-Sastre A., et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 80 December (23) (2006) 11628-11637
31. Cheung Y.K., Cheng S.C., Sin F.W., and Xie Y. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 23 December (5) (2004) 629-638
32. Herrmann J.E., Wang S., Zhang C., Panchal R.G., Bavari S., Lyons C.R., et al. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine 24 July (31-32) (2006) 5872-5880
33. Stratford R., Douce G., Zhang-Barber L., Fairweather N., Eskola J., and Dougan G. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 19 November (7-8) (2000) 810-815
34. Wang S., Chou T.H., Sakhatskyy P.V., Huang S., Lawrence J.M., Cao H., et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 79 February (3) (2005) 1906-1910
35. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14 January (2) (1998) 151-155
36. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90 September (18) (1993) 8392-8396
37. Hou Z.C., and Yang N. Factors affecting codon usage in Yersinia pestis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35 June (6) (2003) 580-586
38. Lindler L.E., Plano G.V., Burland V., Mayhew G.F., and Blattner F.R. Complete DNA sequence and detailed analysis of the Yersinia pestis KIM5 plasmid encoding murine toxin and capsular antigen. Infect Immun 66 December (12) (1998) 5731-5742
39. Wang S., Zhang C., Zhang L., Li J., Huang Z., and Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26 April (17) (2008) 2100-2110
40. Sebbane F., Jarrett C., Gardner D., Long D., and Hinnebusch B.J. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. Infect Immun 77 March (3) (2009) 1222-1229
41. Davis K.J., Fritz D.L., Pitt M.L., Welkos S.L., Worsham P.L., and Friedlander A.M. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 120 February (2) (1996) 156-163
42. Lu S., Manning S., and Arthos J. Antigen engineering in DNA immunization. In: Lowrie DaW R. (Ed). Methods in molecular medicine DNA vaccines (1999), Humana Press 355-374